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INTRODUCTION
Bladder cancer is the seventh most common cancer in the UK, affecting more than 10,000 people each year (16) . The majority of diagnosed patients (75 to 85%) present with non-muscle invasive disease, which is characterised by a probability of recurrence at five years of 31 to 78% (1) The ultimate goal in the management of non-muscle invasive transitional cell carcinoma (TCC) of the bladder is the prevention of disease recurrence and progression. Early cancer detection is an essential prerequisite of successful therapy.
Unfortunately, small papillary bladder tumours and flat urothelial tumours such as carcinoma in situ (CIS) can easily be overlooked during conventional WLC. Indeed, many of the recurrent tumours may be due to the persistence of residual tumour in the bladder after an incomplete TURBT. Moreover, progression to muscle invasive or metastatic TCC is more likely to occur in those with concomitant CIS (1) . Nonmuscle invasive TCC of the bladder is one of the most expensive cancers to manage on a per patient basis, because of its high prevalence, high recurrence rate and the need for long-term cystoscopic surveillance. The total cost of treatment and five year follow-up of patients with non-muscle invasive bladder cancer diagnosed during 2001-2002 in the UK was over £35 million (12) .
Photodynamic diagnosis (PDD) is a technique that has been proposed to enhance tumour detection and resection. The principle of PDD is based on the interaction between a photosensitising agent with a high uptake by tumour cells and light with an appropriate wavelength, which is absorbed by the agent and re-emitted with a different wavelength (18) . We carried out a systematic review of the literature to assess the diagnostic performance of PDD compared with rigid WLC and its effects on patient outcomes.
METHODS

Search strategy
Highly sensitive electronic searches, using both controlled vocabulary and free text terms, were undertaken. The search strategies were originally developed for a systematic review (11) with a wider scope than this review and were designed to include retrieval of studies that assessed selected biomarker tests as well as PDD. 
Study selection
We included studies that assessed the test performance or clinical effectiveness of PDD compared with WLC in people suspected of having bladder cancer or previously diagnosed with non-muscle invasive bladder cancer and on follow-up cystoscopic examination. For test performance both randomised and observational (diagnostic cross-sectional or case-control) studies were included. However casecontrol studies in which the controls were healthy volunteers were excluded. The reference standard was histopathological examination of biopsied tissue and studies had to report or allow the calculation of true and false positives and negatives. For assessment of clinical effectiveness we included only RCTs and the outcomes considered were residual tumour at check cystoscopy, recurrence of bladder cancer over time following initial resection, and progression to muscle invasive disease.
Data abstraction and quality assessment
One reviewer screened the titles (and abstracts if available) of all reports identified by the search strategy. Full-text copies of all studies deemed to be potentially relevant were obtained and two reviewers independently assessed them for inclusion. One of three reviewers extracted details of study design, participants, index, comparator and reference standard tests and outcome data, and another checked the data extraction. Disagreements were resolved by consensus or arbitration by another reviewer.
Two reviewers independently assessed the quality of the included studies using a version of the quality assessment of diagnostic accuracy studies (QUADAS) tool adapted to make it more applicable for assessing reports of tests for bladder cancer. QUADAS is a quality assessment tool for use in systematic reviews of diagnostic studies (17) but it is designed to be adapted to make it applicable to a specific review topic. Disagreements were resolved by consensus or arbitration by a third reviewer.
Quantitative data synthesis
For studies of test performance, separate summary receiver operating characteristic (SROC) curves were derived for patient and biopsy level analysis. These meta-analysis models were fitted using the hierarchical summary receiver operating characteristic (HSROC) model (9) in SAS 9.1. Summary sensitivity, specificity, positive and negative likelihood ratios and diagnostic odds ratios (DORs) for each model were reported as point estimate and 95% confidence interval (CI). Due to the clustering of biopsies within patients, the intervals from the biopsy level analyses were expected to be an underestimate of the true uncertainty.
For studies reporting clinical effectiveness, dichotomous outcome data were combined as relative risk (RR). In the absence of statistical heterogeneity, which was explored using chi-squared tests, I 2 statistics and visual inspection, a fixed effect model was used. Where there was evidence of heterogeneity, data were analysed using a random effects meta-analysis. 
RESULTS
Trial flow
Study characteristics and methodological quality
The 27 diagnostic studies, published in 36 reports enrolled 2949 participants, with 2807 contributing to the analysis. Across 19 studies (2327 participants) reporting this information, 41% of the patients (n=946) were first time presenters with symptoms suspicious of bladder cancer while 59% (n=1381) had previously diagnosed bladder cancer. Further details of the diagnostic studies are shown in Supplementary Table   3 .
In the four RCTs reporting effectiveness outcomes, published in eight reports, the groups were randomised to WLC or PDD, while in the other studies the groups were randomised to WLC or WLC and PDD. In Babjuk and colleagues (2), 33% (20/60) of the PDD group and 45% (28/62) of the WLC group were newly presenting with symptoms suspicious of bladder cancer while 67% (40/60) of the PDD group and 55% (34/62) of the WLC group had previously diagnosed bladder cancer. The remaining studies did not report this information. All four studies used 5-aminolaevulinic acid (5-ALA) as the photosensitising agent. The follow-up periods for the studies were eight years, five years, two years and 10 to 14 days. Kriegmair and colleagues (7) only aimed to evaluate residual tumour following TURBT.
Further details of the effectiveness studies are shown in Supplementary Table 4. Figure 2 summarises the results of the quality assessment for the diagnostic studies. In all studies partial verification bias (all patients received a reference standard test) and test review bias (PDD and WLC were interpreted without knowledge of the results of the reference standard) were avoided. However all studies were judged to suffer from incorporation bias, in that PDD was considered not to be independent of the reference standard test, as biopsies used in the reference standard test were obtained via the PDD procedure. In all four studies reporting effectiveness outcomes it was unclear whether the sequence generation was really random or the treatment allocation was adequately concealed or whether outcomes assessors, care providers or patients were blinded.
Quantitative data synthesis
Diagnostic performance
In the pooled estimates for patient level analysis, based on evidence from five studies, PDD had higher sensitivity than WLC (92%, 95% CI 80 to 100% versus 71%, 95% CI 49 to 93%) but lower specificity (57%, 95% CI 36 to 79% versus 72%, 95% CI 47 to 96%). In the pooled estimates for biopsy level analysis, based on evidence from 14 studies, PDD also had higher sensitivity than WLC (93%, 95% CI 90 to 96% versus 65%, 95% CI 55 to 74%) but lower specificity (60%, 95% CI 49 to 71% versus 81%, 95% CI 73 to 90%). Figure 3 
Across studies, the median sensitivity (range) of PDD compared with WLC for detecting lower risk, less aggressive tumours was broadly similar for patient level detection but higher for PDD for biopsy level detection (Table 1 ). However, for the detection of more aggressive, higher risk tumours the median sensitivity of PDD for both patient and biopsy level detection was higher than WLC. The higher sensitivity of PDD was also reflected in the detection of CIS alone, both for patient and biopsy level detection (Table 1) .
Type of photosensitising agent
Most studies (n = 18) used 5-ALA as the photosensitising agent, while five used hexaminolaevulinate (HAL), two used hypericin and two used either 5-ALA or HAL.
In patient based detection of bladder cancer, across four studies using 5-ALA and three using HAL, the median (range) sensitivity and specificity for 5-ALA was 96% (64 to 100%) and 52% (33 to 67%) respectively, compared with 90% (53 to 96%) sensitivity and 81% (43 to 100%) specificity for HAL. In biopsy based detection of bladder cancer, across 15 studies using 5-ALA, the median (range) sensitivity and specificity for 5-ALA was 95% (87 to 98%) and 57% (32 to 67%), compared with 85% (76 to 94%) and 80% (58 to 100%) for HAL.
Clinical effectiveness
All four studies, involving 544 patients, reported residual tumour rate (pTa and pT1).
The timing of cystoscopy following TURBT ranged from 10 to 14 days, to 10 to 15 weeks after the initial resection. Compared with WLC, the use of PDD was associated with statistically significantly fewer residual pTa and pT1 tumours (RR 0.32, 95% CI 0.15 to 0.70 and RR 0.26, 95% CI 0.12 to 0.57 respectively), with an overall RR of 0.37 (95% CI 0.20 to 0.69). Two studies involving 313 patients reported recurrence-free survival at 12 and 24 months. In the pooled estimates there was a statistically significant difference in favour of PDD at 24 months (RR 1.37, 95% CI 1.18 to 1.59) but not at 12 months (RR 1.40, 95% CI 0.96 to 2.03). The benefits of using PDD at TURBT in reducing tumour recurrence (pooled estimate RR 0.64, 95% CI 0.39 to 1.06) and progression (pooled estimate RR 0.57, 95% CI 0.22 to 1.46) in the longer term were less clear, with the effect estimates favouring PDD without reaching statistical significance.
DISCUSSION
Statement of principal findings
The pooled estimates for both patient and biopsy level analysis showed that PDD had higher sensitivity than WLC for detecting bladder cancer, but lower specificity.
PDD also had a much higher sensitivity than WLC in the detection of more 
including concomitant CIS, the types more likely to be detected by PDD (14) .
Strengths and limitations of the study
In terms of strengths, a recently recommended HSROC model was employed which takes account of the trade off between true and false positives and models between study heterogeneity (8) . Pooled estimates of both patient and biopsy level detection were undertaken.
However biopsy level estimates were likely to be an underestimate of the true uncertainty due to clustering of biopsies within patients.
For reports of clinical effectiveness we focused on RCTs. In terms of limitations, nonEnglish language studies were excluded. Based on screening English language titles or abstracts our searches identified 33 non-English language studies relating to PDD, some of which may have otherwise met the inclusion criteria.
Implications for practice and research
Our results suggest that the appropriate point in the clinical pathway for PDD to be used is in conjunction with rigid WLC during the initial TURBT, and possibly also in conjunction with rigid WLC during surveillance monitoring of high risk patients.
The advantages of higher sensitivity (fewer false negative results, better detection of 
CIS
Patient based detection
83 (41 to 100) 32 (0 to 83) 563 6
Biopsy based detection
86 (54 to 100) 50 (0 to 68) 1756 (7506) 13
Notes:
1. The number of biopsies is the overall total reported by the studies. 2. Number of biopsies. In some studies more biopsies were taken for PDD than WLC and in these cases the higher number used for PDD has been used in the 
